曲美他嗪联合注射用重组人脑利钠肽治疗慢性缺血性心力衰竭的效果

Effect of Trimetazidine combined with Recombinant Human Brain Natriuretic Peptide for Injection in the treatment of chronic ischemic heart failure

目的探讨曲美他嗪联合注射用重组人脑利钠肽治疗慢性缺血性心力衰竭的效果。方法选取2016年10月~2019年10月于辽宁省丹东市第一医院住院治疗的80例慢性缺血性心力衰竭患者作为研究对象,按照随机数字表法将其分为对照组(曲美他嗪治疗,40例)和观察组(曲美他嗪联合注射用重组人脑利钠肽治疗,40例)。两组均治疗7 d,比较两组疗效和不良反应发生情况。比较两组治疗前后左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、每搏量(SV)、心排血量(CO)、左心室射血分数(LVEF)以及血清超氧化物歧化酶(SOD)、丙二醛(MDA)水平。结果观察组总有效率明显高于对照组(P<0.05)。治疗后,两组的LVEDD、LVESD均较治疗前缩短,SV、CO较治疗前增多,LVEF较治疗前升高(P<0.05),且观察组LVEDD、LVESD均较对照组缩短,SV、CO较对照组增多,LVEF较对照组升高(P<0.05)。治疗后,两组血清SOD水平较治疗前升高,MDA水平较治疗前降低(P<0.05),且观察组血清SOD水平较对照组升高,而MDA水平较对照组降低(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论曲美他嗪联合注射用重组人脑利钠肽治疗慢性缺血性心力衰竭效果显著,能明显改善患者的心功能、机体氧化应激状态,同时具有较好的安全性。

Objective To explore the effect of Trimetazidine combined with Recombinant Human Brain Natriuretic Peptide for Injection in the treatment of chronic ischemic heart failure.Methods Eighty patients with chronic ischemic heart failure hospitalized in the First Hospital of Dandong City from October 2016 to October 2019 were selected as research objects,and they were divided into control group(Trimetazidine treatment,40 cases)and observation group(Trimetazidine combined with Recombinant Human Brain Natriuretic Peptide for Injection treatment,40 cases)according to the method of random number table.Both groups were treated for 7 days,and the efficacy and adverse reactions of two groups were compared.Left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),stroke volume(SV),cardiac output(CO),left ventricular ejection fraction(LVEF),serum superoxide dismutase(SOD),malondialdehyde(MDA)levels before and after treatment were compared between two groups.Results Total effective rate of observation group was significantly higher than that of control group(P<0.05).After treatment,LVEDD and LVESD of two groups were shorter than those before treatment,SV and CO were more than those before treatment,LVEF was higher than that before treatment(P<0.05),and LVEDD and LVESD of observation group were shorter than those of control group,SV and CO were more than those of control group,LVEF was higher than that of control group(P<0.05).After treatment,serum SOD level of two groups was higher than that before treatment,MDA level was lower than that before treatment(P<0.05),and serum SOD level of observation group was higher than that of control group,while MDA level was lower than that of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion Trimetazidine combined with Recombinant Human Brain Natriuretic Peptide for Injection has a significant effect on chronic ischemic heart failure,which can significantly improve the cardiac function and oxidative stress state of patients,and have a good safety.